Collegium reports record Q1 revenue $144.8M, adjusted EPS $1.32, reaffirms FY23 guide

COLLEGIUM PHARMACEUTICAL, INC

2023-Q1 EPS reported -$0.51 revenue$144,767,000

Record product revenue net of $144.8M, up 73% YoY from $83.8M.
Non-GAAP adjusted net income $51.7M with adjusted EPS $1.32 vs $0.71 YoY.
Adjusted EBITDA $87.6M, up 101% YoY from $43.5M.
Cash balance $269.5M; completed $241.5M convertible note offering due 2029.
Reaffirmed FY23 product revenue $565-580M and adjusted EBITDA $355-370M.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

COLLEGIUM PHARMACEUTICAL, INC reported Full Year 2023 results: revenue $565.0 to $580.0 million. Guidance reaffirmed.

Period: Full Year 2023
Revenue: $565.0 to $580.0 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

The Company reaffirms its full-year 2023 guidance for Product Revenues, Net, Adjusted Operating Expenses and Adjusted EBITDA: Product Revenues, Net $565.0 to $580.0 million Adjusted Operating Expenses (Excluding Stock-Based Compensation) $135.0 to $145.0 million Adjusted EBITDA (Excluding Stock-Based Compensation) $355.0 to $370.0 million

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

COLLEGIUM PHARMACEUTICAL, INC filing history →

Source: SEC EDGAR

accession 0001558370-23-008080

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.